Jerome Maxfield
Nurse Practitioner · Rehoboth Beach, DENPI 1528129376
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.6% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,679, more than ten times the $165 reported in 2021.
Across 33 payments — averaging $75.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$433
- Incyte Corporation$222
- AstraZeneca$215
- Beone Medicines USA, Inc.$150
- Gilead$146
- Daiichi Sankyo Inc.$145
- plus $1K from 17 others
What the payments were for
- Food & beverage$2,28992%
- Education$2118%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $433 |
| Incyte Corporation | 2 | $222 |
| AstraZeneca | 3 | $215 |
| Beone Medicines USA, Inc. | 1 | $150 |
| Gilead | 2 | $146 |
| Daiichi Sankyo Inc. | 2 | $145 |
| Seagen Inc. | 2 | $142 |
| Astellas Pharma Global Development | 1 | $126 |
| Dova Pharmaceuticals | 1 | $125 |
| AbbVie | 1 | $123 |
| Boston Scientific | 1 | $110 |
| Astellas Pharma US Inc | 1 | $99 |
| Puma Biotechnology, Inc. | 1 | $82 |
| Medtronic | 1 | $82 |
| Bayer | 1 | $77 |
| Johnson & Johnson | 1 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Tersera Therapeutics LLC | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Genmab U.S., Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Array Biopharma Inc | 1 | $19 |
| Deciphera Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,500 in reported general payments places this provider in the 85th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 16 | $170 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Rehoboth Beach
- Melissa TaylorRehoboth Beach$4K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
- Jennifer HubbardWilmington$12K
- Kathleen HudsonMillville$10K
- Nancy Townsend O'DayMillsboro$8K
- Funmilola OlaoyeNewark$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.